The 60 references in paper A. Danilenko A., S. Shakhtarina V., А. Даниленко А., С. Шахтарина В. (2014) “Изменения в легких вследствие лекарственной терапии больных лимфомой Ходжкина // Pulmonary lesions due to drug therapy of Hodgkin's lymphoma” / spz:neicon:pulmonology:y:2013:i:1:p:95

1
Meadors M., Floyd J., Perry M.C. Pulmonary toxicity of chemotherapy. Semin. Oncol. 2006; 33 (1): 98–105.
(check this in PDF content)
2
Bredenfeld H., Franklin J., Nogova L. et al.Severe pul$ monary toxicity in patients with advanced$stage Hodgkin`s disease treated with modified bleomycin, doxorubicin, cyclophosfamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin`s Lymphoma Study Group. J. Clin. Oncol. 2004; 22: 2424–2429.
(check this in PDF content)
3
Torrisi J.M., Schwartz L.H., Gollub M.J. CT findings of chemotherapy$induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011; 258 (1): 41–56.
(check this in PDF content)
4
Даниленко А.А., Шахтарина С.В., Афанасова Н.В. и др. Изменения в легких у больных лимфомой Ходжкина после химиотерапии по схемам СОРР, ABVD, BEA$ COPP и облучения средостения в суммарной очаговой дозе 20–30 Гр. Клин. Онкогематол. 2010; 3 (4): 354–358.
(check this in PDF content)
5
Roig J.Pulmonary toxicity caused by cytotoxic drugs. Clin. Pulm. Med. 2006; 13 (1): 53–62.
(check this in PDF content)
6
Umezawa H., Meaeda K., Takeuchi T. et al.New antibiotics, bleomycin A and B. J. Antibiot. Ser. A. 1966; 19: 200–2005.
(check this in PDF content)
7
Martin W.G., Ristow K.M., Habermann T.M. et al. Bleo$ mycin pulmonary toxicity has a negative impact on the out$ come of patients with Hodgkin`s lymphoma. J. Clin. Oncol. 2005; 23: 7614–7620.
(check this in PDF content)
8
Ohnuma T., Holland J.F., Masuda h. et al.Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer (Philad.) 1974; 33: 1230–1238.
(check this in PDF content)
9
Santrack P.J., Askin F.B., Wells R.J. et al.Nodular form of bleomycin$related pulmonary injury in patients with osteogenic sarcoma. Cancer (Philad.) 1989; 64: 806–811.
(check this in PDF content)
10
Holoye P.Y., Luna M.H., Mackay B. et al. Bleomycin hyper$ sensitivity pneumonitis. Ann. Intern. Med. 1978; 88: 47–49.
(check this in PDF content)
11
Vender Els N.J., Stover D.E.Chemotherapy$induced lung disease. Clin. Pulm. Med. 2004; 11 (2): 84–91.
(check this in PDF content)
12
Jules2Elysee K., White D.A. Bleomycin$induced pulmonary toxicity. Clin. Chest Med. 1990; 11: 1–20.
(check this in PDF content)
13
Simpson A.B., Paul J., Graham J. et al.Fatal bleomycin pul$ monary toxicity in the west of Scotland 1991–95: a review of patients with germ cell tumours. Br. J. Cancer 1998; 78: 1061–1066.
(check this in PDF content)
14
Burger R.M., Pesach J., Horwitc S.B.Activated bleomycin: a transient complex of drug, iron and oxygen that degradates DNA. J. Biol. Chem. 1981; 256: 1636–1644.
(check this in PDF content)
15
Schirner M., Hoffmann J., Menrad A. et al. Antiangiogenetic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcino$ ma models. Clin. Cancer. Res. 1998; 4: 1331–1336.
(check this in PDF content)
16
Adamson I.j.R., Bowden D.H.The pathogebesis of bleo$ mycine$induced pulmonary fibrosis in mice. Am. J. Pathol. 1974; 77: 185–191.
(check this in PDF content)
17
Barneveld P.W.C., Sleijfer D.T., Van der Mark T.W. et al. The natural course of bleomycin induced pneumonitis (BIP): a follow$up study in eight patients. Am. Rev. Respir. Dis. 1987; 135: 48–51.
(check this in PDF content)
18
Piguet P.F.Cytokines involved in pulmonary fibrosis. Int. Rev. Exp. Pathol.1993; 34: 173–181.
(check this in PDF content)
19
Hagimoto N., Kuwano K., Nomoto Y. et al.Apoptosis and expression of Fas / Fas ligand mRNA in bleomycin$induced pulmonary fibrosis in mice. Am. J. Respir. Cell. Mol. Biol. 1997; 16: 91–101.
(check this in PDF content)
20
Kuwano K., Hagimoto N., Kawasaki M. et al.Essential roles of the Fas / Fas ligand pathway in the development of pul$ monary fibrosis. J. Clin. Invest. 1999; 104: 13–19.
(check this in PDF content)
21
Phan S.H., Kunkel S.L.Lung cytocine production in bleo$ mycin$induced pulmonary fibrodsis. Exp. Lung Res. 1992; 18: 29–43.
(check this in PDF content)
22
Santana A., Saxena B., Noble N.A. et al. Increased expres$ sion of transforming growth factor βisoforms (β1, β2, β3) in bleomycin$induced pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 1995; 13: 34–44.
(check this in PDF content)
23
Doelman C.J.A., Bast A. Oxygen radicals in lung pathology. Free Radic. Biol. Med. 1990; 9: 381–400.
(check this in PDF content)
24
Herman E.H., Hasinoff B.B., Zhang J. et al.Morphologic and morphometric evaluation of the effect of ICRF$187 on bleomycin$induced pulmonary toxicity. Toxicology 1995; 98: 163–175.
(check this in PDF content)
25
Nici L., Calabresi P. Amifostine modulation of bleomycin$ induced lung injury in rodents. Semin. Oncol. 1999; 26: 28–33.
(check this in PDF content)
26
Moseley P.L., Hemken C., Hunninghake G.W. Augmentation of fibroblast proliferation by bleomycin. J. Clin. Invest.1986; 78: 1150–1154.
(check this in PDF content)
27
Schmidt J.A., Mizel S.B., Cohen D. et al. Interleukin$1: a potential regulator of fibroblast proliferation. J. Immunol. 1982; 128: 2177–2182.
(check this in PDF content)
28
Sugerman B.J., Aggarval B.B., Figary I.S. et al. Recombinant human tumor necrosis factor β: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943–945.
(check this in PDF content)
29
Zhang K., Flanders K.C., Phan S.H. Cellular localization of transforming growth factor αexpression in bleomycin$ induced pulmonary fibrosis. Am. J. Pathol.1995; 147: 352–361.
(check this in PDF content)
30
Giri S.N., Hyde D.M., Hollinger M.A.Effect of antibody to transforming growth factor βon bleomycin induced accu$ mulation of lung collagen in mice. Thorax 1993; 48: 959–966.
(check this in PDF content)
31
White D.A., Stover D.E.Severe bleomycin$induced pneu$ monitis: clinical features and response to corticosteroids. Chest 1984; 86: 723–728.
(check this in PDF content)
32
Lena M., Guzzon A., Monfardini S. et al.Clinical, radio$ logic and histopathological studies on pulmonary toxicity induced by treatment with bleomycin. Cancer Chemother. Rep. 1972; 56: 343–355.
(check this in PDF content)
33
Ngeow J., Tan I.B., Kanesvaran R. et al. Prognostic impact of bleomycin$induced pneumonitis on the outcome of Hodgkin`s lymphoma. Ann. Hematol. 2011; 90 (1): 67–72.
(check this in PDF content)
34
Yagoda A., Makherji B., Young C. et al. Bleomycin: an anti$ tumor antibiotic; clinical experience in 274 patients. Ann. Intern. Med.1972; 77 (6): 861–870.
(check this in PDF content)
35
Flieder D.B., Travis W.D.Pathologic characteristics of drug$ induced lung disease. Clin. Chest Med. 2004; 25 (1): 37–45.
(check this in PDF content)
36
Comis R.L., Kuppinder M.S., Ginsberg S.J. et al.Bleomycin$ induced pulmonary function abnormalities. Cancer Res. 1979; 39 (12): 5076–5080.
(check this in PDF content)
37
Wolkowicz J., Sturgeon J., Ravji M. et al. Bleomycin$induced pulmonary function abnormalities.Chest 1992; 101: 97–101.
(check this in PDF content)
38
Sorensen P.G., Rossing N., Roth M.Carbon monoxide dif$ fusing capacity: a reliable indicator of bleomycin$induced pulmonary toxicity. Eur. J. Respir. Dis. 1985; 66: 333–340.
(check this in PDF content)
39
Sleijfer S., van der Mark T.W., Schafford Koops H. et al. Decrease in pulmonary function during bleomycin$con$ taining combination chemotherapy for testicular cancer: not only a bleomycin effect. Br. J. Cancer 1995; 71 (1): 120–123.
(check this in PDF content)
40
Hirsch A., Vander Els N., Straus D.J. et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irra$ diation on pulmonary function and symptoms in early$stage Hodgkin`s disease. J. Clin. Oncol. 1996; 14: 1297–1305.
(check this in PDF content)
41
Collis C.H.Lung damage of cytotoxic drugs. Cancer Chemother. Pharmacol. 1980; 4: 17–27.
(check this in PDF content)
42
McLeod B.F., Lawrence H.J., Smith D.W. et al. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer (Philad.) 1987; 60: 2617–2622.
(check this in PDF content)
43
Bauer K.A., Skarin A.T., Balikian J.P. et al.Pulmonary com$ plications associated with combination chemotherapy pro$ grams containing bleomycin. Am. J. Med. 1983; 74: 557–563.
(check this in PDF content)
44
Lower E.E., Strohofer S., Baughman R.P.Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am. J. Med. Sci. 1988; 295: 193–197.
(check this in PDF content)
45
Crooke S.T., Comis R.L., Einhorn L.H. et al. Effect of varia$ tions in renal function on the clinical pharmacology of bleomycin administrated as an iv bolus. Cancer Treat. Rep.1977; 61: 1631–1636.
(check this in PDF content)
46
Hall S.W., Strong J.E. Broughton A. et al.Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother. Pharmacol. 1982; 9: 22–25.
(check this in PDF content)
47
Sleijfer S., van der Mark T.W., Schraffordt Koops H. et al. Enhanced effects of bleomycin on pulmonary function dis$ turbances in patients with decreased renal function due to cisplatin. Eur. J. Cancer 1996; 32 (3): 550–552.
(check this in PDF content)
48
Horning S.J., Adhikari A., Rizk N. et al.Effect of treatment for Hodgkin`s disease on pulmonary function: results of a prospective study. J. Clin. Oncol. 1994; 12: 297–305.
(check this in PDF content)
49
Macann A., Bredenfeld H., Muller R.P. et al. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced$stage Hodgkin`s lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin`s Lymphoma Study Group. Int. J. Radiat. Oncol. Biol. Phys. 2008; 70: 161–165.
(check this in PDF content)
50
Sogal R.N., Gottlieb A.A., Boutros A.R. et al.Effect of oxygen on bleomycin$induced lung damage. Cleveland Clin. J. Med. 1987; 54: 503–509.
(check this in PDF content)
51
Tryka A.F., Skornik W.A., Godleski J.J. et al. Potentiation of bleomycin$induced lung injury by exposure to 70 % oxygen. Am. Rev. Respir. Dis. 1982; 126: 1074–1076.
(check this in PDF content)
52
Matthews J.Pulmonary toxicity of ABVD chemotherapy and G$CSF in Hodgkin's disease: possible synergy. Lancet 1993; 342: 988.
(check this in PDF content)
53
Saxman S.B., Nichols C.R., Einhorn L.H. Pulmonary toxic$ ity in patients with advanced$stage germ cell tumors receiv$ ing bleomycin with and without granulocyte colony stimu$ lating growth factor. Chest 1997; 111: 657–660.
(check this in PDF content)
54
Wedgwood A., Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin`s lymphoma. Clin. Lymphoma Myeloma 2007; 8 (Suppl. 2): 63–66.
(check this in PDF content)
55
Piguet P.F., Vesin C., Grau G.E. et al. Interleukin 1 receptor antagonist (IL$Ira) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or cilica. Cytokine 1993; 5 (1): 57–61.
(check this in PDF content)
56
Sugahara K., Iyama K., Kuroda M.J. et al.Double intratra$ cheal installation of keratinocyte growth factor prevents bleomycin$induced lung fibrosis in rats. J. Pathol. 1998; 186: 90–98.
(check this in PDF content)
57
Lossos I.S., Or R., Goldstein R.H. et al. Amelioration of bleomycin$induced pulmonary injury by cyclosporin A. Exp. Lung. Res. 1996; 22: 337–349.
(check this in PDF content)
58
Piguet P.F., Tacchini2Cottier F., Vesin C. Administration of anti$TNF$alpha or anti$CD11a antibodies to nirmal adult mice dicreases lung and bone collagen content: evidence for an effect on platelet consumption. Am. J. Respir. Cell. Mol. Biol. 1995; 12 (2): 227–231.
(check this in PDF content)
59
Sharma S.K., MacLean J.A., Pinto C. et al.The effect of an anti$CD3 monoclonal antibody on bleomycin induced lym$ phokine production and lung injury. Am. J. Respir. Dis. 1996; 154: 193–200.
(check this in PDF content)
60
Nettelbladt O., Tengblad A., Hallgren R. High$dose corticos$ teroids during bleomycin$induced alveolitis in the rat do not suppress the accumulation of hyaluronan (hyaluronic acid) in lung tissue. Eur. Respir. J. 1990; 3: 421–428. Информация об авторах
(check this in PDF content)